Advaxis (NASDAQ:ADXS): $0.45 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 1.51. The value of trades done on upticks was $1.34 million, whereas, trades done on downticks were valued at $0.88 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.25 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.25 million. Advaxis (NASDAQ:ADXS) fell $0.18 traded at $8.24, a change of -2.14% over the previous day. The stock is 4.17% for the week.
In an insider trading activity, The Securities and Exchange Commission has divulged that Mckearn Thomas J, director of Advaxis, Inc., had unloaded 4,100 shares at an average price of $7.45 in a transaction dated on May 13, 2016. The total value of the transaction was worth $30,545. Currently the company Insiders own 4.56% of Advaxis shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.71% . Institutional Investors own 60.55% of Advaxis shares. During last six month period, the net percent change held by insiders has seen a change of -7.26%.
The company shares have dropped -55.50% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $22.20 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $8.32 and the 200 Day Moving Average price is recorded at $8.27. Advaxis (NASDAQ:ADXS): The stock opened at $8.58 on Wednesday but the bulls could not build on the opening and the stock topped out at $8.59 for the day. The stock traded down to $8.05 during the day, due to lack of any buying support eventually closed down at $8.23 with a loss of -2.26% for the day. The stock had closed at $8.42 on the previous day. The total traded volume was 593,875 shares.
Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.